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Nationwide prevalence of human papillomavirus
infection and viral genotype distribution in 37
cities in China
Rong Wang1,3†, Xiao-lei Guo2†, G. Bea. A. Wisman3, Ed Schuuring4, Wen-feng Wang2, Zheng-yu Zeng2,
Hong Zhu5 and Shang-wei Wu2,1*
Abstract
Background: Type-specific high-risk HPV (hrHPV) infection is related to cervical carcinogenesis. The prevalence of
hrHPV infection varies geographically, which might reflect the epidemiological characteristics of cervical cancer
among different populations. To establish a foundation for HPV-based screening and vaccination programs in China,
we investigated the most recent HPV prevalence and genotypic distributions in different female age groups and
geographical regions in China.
Methods: In 2012, a total of 120,772 liquid-based cytological samples from women enrolled for population- or
employee-based cervical screening in 37 Chinese cities were obtained by the Laboratory of Molecular Infectious
Diseases of Guangzhou KingMed. A total of 111,131 samples were tested by Hybrid Capture II and the other
9,641 were genotyped using the Tellgenplex™ HPV DNA Assay.
Results: The total positive rate for hrHPV was 21.07 %, which ranged from 18.42 % (Nanchang) to 31.94 % (Haikou)
and varied by region. The regions of Nanchang, Changsha, Hangzhou, Chengdu, Fuzhou, Guangdong, and Guiyang
could be considered the low prevalence regions. Age-specific prevalence showed a “two-peak” pattern, with the
youngest age group (15–19 years) presenting the highest hrHPV infection rate (30.55 %), followed by a second
peak for the 50–60-year-old group. Overall, the most prevalent genotypes were HPV16 (4.82 %) and HPV52 (4.52 %),
followed by HPV58 (2.74 %). Two genotypes HPV6 (4.01 %) and HPV11 (2.29 %) were predominant in the low-risk HPV
(lrHPV) type, while the mixed genotypes HPV16 + 52 and HPV52 + 58 were most common in women with multiple
infections.
Conclusions: This study shows that HPV infection in China has increased to the level of an “HPV-heavy-burden” zone in
certain regions, with prevalence varying significantly among different ages and regions. Data from this study represent
the most current survey of the nationwide prevalence of HPV infection in China, and can serve as valuable reference to
guide nationwide cervical cancer screening and HPV vaccination programs.
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Background
HPV infection can cause a variety of genital diseases, and
type-specific persistent infection of high-risk HPV (hrHPV)
cases is strongly associated with cervical carcinogenesis [1].
Cervical cancer is the third most common type of cancer in
women worldwide [2]. Effective implementation of cervical
screening programs in developed countries has resulted in
a steady reduction in the incidence of cervical cancer [3].
However, in China, the most populous country, cervical
cancer remains the second leading cause of cancer deaths
among 15- to 44-year-old females [4]. It is estimated that
75,434 women are diagnosed with cervical cancer annually
(11.3/100,000) and 33,914 (45.0 %) of those women die be-
cause of cervical cancer [5, 6].
To date, more than 200 HPV genotypes have been
identified, and ~40 HPV genotypes have been detected
in the female genital tract. HPV16 and HPV18 are well
known as oncogenic genotypes; additionally, HPV31,
HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56,
HPV58, HPV59, HPV68, HPV69, and HPV 82 are also
closely associated with cervical cancer. Therefore, all of
these genotypes are classified as “high-risk” HPV. Mean-
while, “low-risk” genotypes, including HPV6, HPV11,
HPV42, HPV43, and HPV44 are the causative agents
for benign or low-grade changes in cervical cells, such
as genital warts [7, 8].
The current hrHPV detection is supposed to serve as
an additional approach for the early diagnosis of cervical
cancer, and was implemented to complement less sensi-
tive and non-objective cytology-based methods [3]. The
high negative predictive value of hrHPV testing is ap-
plicable for the indication of a low-risk population, in
which the cervical cancer screening interval can be safely
extended [3]. Based on the results of clinical trials, several
European countries will implement hrHPV testing as the
primary screening modality [9]. In addition to HPV screen-
ing, HPV vaccination has been shown to be an effective
strategy against HPV infection and has been recently imple-
mented in most western countries. Although Cervarix
(HPV16/18) and Gardasil (HPV6/11/16/18) protect against
infection by HPV16 and HPV18, these vaccines provide no
effect on some of the hrHPV types found in at least 25 % of
cervical cancers [10]. Furthermore, the role of non-vaccine
HPV types in the development of lesions remains un-
known, and it remains possible that non-vaccine HPV types
could replace these vaccine types as the causative agents for
cervical precancerous lesions and cancer in vaccinated co-
horts without sufficiently broad cross-protection [10].
The prevalence of HPV infection and type-specific
distribution vary greatly both between nations [11], and
between different regions within countries [12]. Addition-
ally, several other risk factors can influence the prevalence
of HPV, including genetic variation, sexual behavior (age
at first sexual intercourse and individuals with multiple
sex partners), biological predisposition of the immature
cervix, and immunodeficiency [13]. Hence, surveillance of
the general population is needed to assess the clinical ben-
efits of screening and vaccination strategies.
Obtaining large-scale information about the epidemio-
logical features of HPV in China is critical for global HPV
prevention strategies, because of the need to understand
the geographic diversity and age distribution of HPV in-
fections. Although a pilot project aimed to measure the
hrHPV infection rate and cervical cancer screening was
conducted in a few Chinese areas in 1999 [14], and several
similar larger scale investigations were carried out that
covered more regions that were conducted in 2003, 2008,
2009, and 2012 [15–18], the available data remain insuffi-
cient [9] and outdated. Obtaining a more current dataset
will also provide a reference for effective screening
and vaccination. Herein, we describe a nationwide cross-
sectional and large-scale study that had the following aims:
1) to reveal the prevalence of HPV in regions not yet
investigated; 2) to follow-up potential changes in HPV
infection in regions that have been previously studied;
3) to clarify the genotypic distribution of HPV in different
regions and age-grouped populations. These data should
expand the data available regarding HPV-related cervical




This study was approved by the Ethics Committee of
Tianjin Medical University in accordance with the Ethical
Principles for Biomedical Research Involving Human Sub-
jects (Ministry of Health of the People’s Republic of China)
and Declaration of Helsinki for Human Research of 1974
(last modified in 2000). Samples were originally obtained
from clinical settings for laboratory diagnoses. After diag-
nostic testing, excess samples were anonymized and kept
for this study. Informed consent was obtained from each
female participant. For those individuals younger than
18 years old, the consent form was signed by the parents
of each participant.
Study population
KingMed Diagnostics is the largest reference laboratory
in China and provides diagnostic testing services for over
13,000 hospitals in 18 provinces and 4 municipalities across
the nation. From January to December of 2012, a total
of 120,772 samples were obtained for population- or
employee-based screening from 37 cities, belonging to
18 regions (Guangdong province was regarded as one
region as 20 cities in this investigation were located in
that province). Fig. 1 shows a map of all of the geograph-
ical sites in China and the 18 regions were further grouped
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into 4 macro-geographical regions (East, West, South,
and North).
The women enrolled from population- or employee-
based cervical cancer screening programs ranged in
age from 15 to 60 years old, were sexually active, and
had no history of cervical treatment before the screening.
Exclusion criteria included current pregnancy, <3 months
post-partum, HIV-seropositivity, and a history of either
hysterectomy or treatment for cervical cancer.
Among all of the samples, 111,131 were collected from
15 regions (Haikou, Chongqing, Jinan, Jilin, Shenyang,
Tianjin, Shanghai, Nanning, Guangdong, Guiyang, Fuzhou,
Hangzhou, Chengdu, Changsha, and Nanchang; Fig. 1)
and were analyzed using Hybrid Capture II (HCII); 105,069
(94.5 %) of these samples could be grouped by age. The
other 9641 samples from 10 regions (Shanghai, Guiyang,
Xi’an, Guangdong, Nanning, Changsha, Hefei, Kunming,
Shenyang, and Jilin; Fig. 1) were genotyped using the Tell-
genplex™ HPV DNA Test and age data were available for
9,194 (95.4 %) samples.
Specimen collection
Following currently accepted protocols of practice, cervico-
vaginal cells at the transformation zone of the uterine
cervix were collected by a gynecologist or a trained
gynecologist assistant with a standard cytobrush (with a
spatula), then were resuspended in a standard transport
medium (STM) and stored at 4 °C [19]. All specimens
were coded without knowledge of the subjects. Subse-
quently, all samples were shipped to the lab of KingMed
Diagnostics for HPV testing within 24 h.
Hybrid Capture II (HCII)
Liquid-based samples were processed by following the
instructions included in the Digene sample conversion
kit. The hrHPV DNA panel of 13 pooled types (HPV16,
HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51,
HPV52, HPV56, HPV58, HPV59, and HPV68) was exam-
ined using the HCII HPV DNA test (Digene Corporation,
Gaithersburg, MD, USA). Data were calculated as a ratio
of mean relative light unit (RLU) for the sample to the
Fig. 1 National map of China showing all the geographical sites included in this study
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mean RLU values for the assay of a positive calibrator
(PC). A RLU-to-PC ratio >1 (~1.08 pg DNA/ml) was de-
fined as a positive result [20, 21].
Tellgenplex™ HPV DNA Test
HPV genotyping was performed using the Tellgenplex™
HPV DNA Test (Tellgen Life Science Co., Shanghai,
China). The assay can be used to detect and genotype 26
HPV genotypes including 19 hrHPV genotypes (HPV16,
HPV18, HPV26, HPV31, HPV33, HPV35, HPV39, HPV45,
HPV51, HPV52, HPV53, HPV55, HPV56, HPV58, HPV59,
HPV66, HPV68, HPV82, and HPV83) and 7 lrHPV geno-
types (HPV6, HPV11, HPV40, HPV42, HPV44, HPV61,
and HPV73). The Tellgenplex HPV™ kit was used to sim-
ultaneously examine the presence or absence of the most
common 26 HPV genotypes in a single test by multiplex
PCR combined with Luminex technology [22, 23]. The
three steps of DNA extraction, PCR amplification, and
hybridization were included in the procedure and a
template of 10–20 pg/ml HPV DNA was needed for each
assay.
Statistical analyses
Region-specific prevalence of HPV
The HPV infection rate in each region was calculated by
dividing the number of HPV-positive samples by the
total number of samples that were successfully tested for
HPV. A binomial 95 % confidence interval (95 % CI)
was estimated for each calculation of the prevalence of
HPV. Chi-squared (χ2) tests were used to compare dif-
ferences among all regions and every two regions.
Age-specific prevalence
The HPV infection rate was estimated within 5 age groups
(15–19, 20–29, 30–39, 40–49, and 50–60). A binomial
95 % confidence interval (95 % CI) was estimated, and
P-values for age trends of HPV infection were analyzed
using the linear-by-linear association test. Differences
between each pairing of two age groups were compared
by the chi-squared (χ2) test. Multiple comparisons were
performed using the Bonferoni step-down procedure to
minimize an inflated risk of type 1 error [24]; P < 0.05
was considered statistically significant.
HPV-type-specific prevalence
The frequency of each hrHPV and lrHPV genotype was
presented in hrHPV-positive samples and lrHPV-positive
samples, respectively.
All statistical analyses were conducted using SPSS20.0
software (SPSS lnc., Chicago, IL, USA).
Results
The total prevalence of hrHPV infection
The total hrHPV infection rate was 21.07 % (95 % Cl
20.83–21.31 %). The prevalence of hrHPV infection dif-
fered significant among the various regions (P < 0.001).
The regions with the highest hrHPV prevalence were
Haikou (31.94 %) and Chongqing (27.29 %). By contrast,
Nanchang, Changsha, Hangzhou, Chengdu, Fuzhou,
Guangdong, and Guiyang could be grouped into the low
prevalence regions (Table 1).
As shown in Fig. 2, hrHPV infection was associated with
age. The group of 15–19-year-olds showed the highest
prevalence (30.55 %), followed by the 50–60-year-olds
(23.30 %). The total infection rate of hrHPV was associ-
ated with age (P < 0.001, Additional file 1: Table S1). After
the highest peak, the prevalence declined, but then the
infection rate significantly increased again in the 50–
60-year-old group compared with the 40-49-year-old
group (P < 0.001, Additional file 1: Table S1). Among
the four macro-regions, only the south showed a similar
trend with the overall age-specific hrHPV prevalence,
whereas the other three macro-geographic regions did not
show significant differences among all five age groups
(Fig. 2, Additional file 1: Table S1).





Infection 95 % CI of infection
rate (%) rate (%)
Haikou 221 692 31.94 28.47–35.41
Chongqing 191 700 27.29 23.99–30.59
Jinan 2,651 10,306 25.72 24.88–26.57
Shenyang 98 387 25.32 20.99–29.65
Jilin 360 1,423 25.3 23.04–27.56
Tianjin 807 3,220 25.06 23.57–26.56
Shanghai 118 522 22.61 19.02–26.20
Nanning 1,976 8,869 22.28 21.41–23.15
Guiyang 597 2,919 20.45 18.99–21.91
Guangdong 14,567 72,763 20.02 19.73–20.31
Fuzhou 441 2,213 19.93 18.26–21.59
Chengdu 375 1,886 19.88 18.08–21.68
Hangzhou 649 3,269 19.85 18.49–21.22
Nanchang 290 1,574 18.42 16.51–20.34
Total 23,413 111,131 21.07 20.83–21.31
HrHPV infection rate was different among all the regions using chi-squared
test (P < 0.001). Subsequently, multiple comparisons were performed using the
Bonferoni step-down procedure: marginal differences between the two most
heavy-burdened cities of Haikou and Chongqing (P = 0.057), and no difference
was found among the second group cities, including Jinan, Shenyang, Jilin,
and Tianjin (P = 0.892), as well as the low infection rate group that included
Nanchang, Changsha, Hangzhou, Chengdu, Fuzhou, Guangdong, and
Guiyang (P = 0.758)
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The distribution of variant HPV genotypes
Among the well-recognized 26 HPV genotypes, all geno-
types except HPV73 were examined using the Tellgenplex
technique. The total infection rate of each genotype among
all of the samples and the distributions of each genotype in
the HPV-positive individuals were respectively evaluated.
In descending order, the infection rate and distribution are
shown in Table 2: the most common hrHPV types were
HPV16 (18.02 %) and HPV52 (16.9 %) (P = 0.288), more-
over, HPV6 (45.80 %), HPV11 (26.15 %), and HPV61
(14.20 %) were common in lrHPV.
Regarding the region-specific distribution of hrHPV, the
top three genotypes were analyzed in each region. HPV16,
HPV58, and HPV52 were dominant in six regions—-
Guiyang, Xi’an, Guangdong, Nanning, Changsha, and She-
nyang—although the orders of the three genotypes showed
variation in different regions (Additional file 2: Table S2).
However, three different top patterns were observed:
HPV16, HPV18, and HPV83 in Shanghai; HPV16, HPV33,
and HPV82 in Hefei; HPV16, HPV56, and HPV59 in
Kunming; as well as HPV16, HPV52, and HPV58 in Jilin
(Additional file 2: Table S2).
For lrHPV, HPV11 was the most common genotype in
Shanghai and Kunming, while HPV6 was the most fre-
quent genotype in all of the other regions (Additional
file 2: Table S2). The distribution of the top three HPV
genotypes was also determined on the basis of age. For
hrHPV, HPV16, HPV52, and HPV58 were dominant
among all of the age groups, except the group of 15–19-
year-olds, in which HPV52, HPV16, and HPV59 were
the major genotypes (Additional file 1: Table S3). For
lrHPV, HPV6 was the leading genotype in all of the age
groups, and the second most commonly detected geno-
type was HPV11 in the younger age groups (i.e., the
groups of 15–19, 20–29, and 30–39), while in the older
groups (40–49 and 50–60) HPV61 was the most prevalent
lrHPV type (Additional file 1: Table S3).
Infection with multiple HPVs was detected in a total of
486 specimens (5.04 %), among which 434 (16.82 %) and 52
(6.16 %) were infected with hrHPVs and lrHPVs, respect-
ively. In the multiple hrHPV infection individuals, the
frequencies of 6, 5, 4, 3, and 2 genotypes were 0.23 %,
1.84 %, 4.61 %, 17.74 %, and 75.58 %, respectively, and three
genotypes showed higher positive rates, i.e., HPV16
(35.02 %), HPV52 (32.26 %), and HPV58 (21.20 %) (Fig. 3).
The top most common combinations of strains were
HPV16 +HPV52 (26 cases) and HPV52 +HPV58 (14 cases)
(Additional file 1: Table S3.). For the individuals with multiple
lrHPV infections, the proportion of those with 4, 3, and 2
genotypes were 1.92 %, 3.85 %, and 94.23 %, respectively.
Among different regions, the highest incidence of
multiple hrHPV and lrHPV infections were in Shanghai
(19.51 %) and Nanning (3.13 %), respectively. The dis-
tribution of dual, triple, quad and up multiple hrHPV in-
fections in each city showed in Fig. 4. Similar to the
overall age trend, of 472 cases with accessible age infor-
mation, after the first peak in the 15–19-year-olds, an-
other peak was observed in 50–60-year-old individuals
both for hrHPV and lrHPV (P < 0.001; Additional
file 1: Fig. S1.)
Fig. 2 Age-specific hrHPV infection by HCII
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Discussion
This is one of the few nationwide investigations of high-
and low-risk HPV in a large-scale screen of the Chinese
population. Because of regional differences, the popula-
tion composition, and the sampling periods, the reported
prevalence varies from study to study, but the most the
heavily burdened HPV regions are Sub-Saharan Africa
(24.0 %), Eastern Europe (21.4 %), Latin America (16.1 %),
and Southeastern Asia (14 %) [25]. In this present survey,
the overall hrHPV-positive rate was 21.07 % (95 % Cl
20.83–21.31 %), which increased in levels within HPV-
heavy-burden countries and was higher than the average
global level.
It is possible that the variable HPV prevalence in
China occurs because of the large Chinese population
and its territories. Meanwhile, economic conditions,
cultural habits, and population migrations have affected
Chinese lifestyles and health [11, 15, 26]. Based on
population-based screening results that have been pre-
viously reported, the overall prevalence of hrHPV varies
from 9.9–27.5 % in China [15]. The highest infection
rate is in Shanxi, a region with a heavy burden of cervical
cancer in China. By contrast, the lowest infection rate was
detected in Beijing, the capital of China with prosperous
economic and more robust healthcare system. The infec-
tion rates in other regions were ~15–20 %, and a pool ana-
lysis that included 17 populations from 9 regions showed
that the positive rate of hrHPV infection was 17.7 % [27].
Together, the overall hrHPV-positive rate in this present
study was found to have increased slightly.
Compared with region-based data, the rates obtained in
this present study were higher than those previously re-
ported for Shanghai [28, 29], Shenyang [28], Guangdong
[30, 31], and Hangzhou [32] (Additional file 1: Table S5).
Additionally, some newly studied regions in this present
survey showed high hrHPV incidences, for example
HaiKou (31.94 %) and Chongqing (27.29 %), and several
cities in the North, including Jinan, Jilin, and Tianjin.
These data showed that hrHPV infection is becoming
more serious, as the infection rate is increasing in many
regions, and some of those regions may soon reach the
level of a heavy burden of infection. Notably, great ad-
vances in screening strategy and laboratory methods could
also have partially contributed to the increased prevalence.
Regarding the hrHPV prevalence in different age groups,
a meta-analysis conducted by Bruni et al. [25] showed a bi-
modal age distribution, with the peak of HPV infection oc-
curring within a younger age group (just after beginning
sexual relations). Globally, the lower prevalence of infection
in the middle age group was accompanied by a gradual
reduction in the incidence in developing countries or a
second peak in developed countries [25]. The trend
wherein hrHPV infection shows high rates in younger
groups and low rates in middle age groups reflects the
natural history of HPV infection. Young females are
sensitive to HPV soon after beginning of sexual activity
because of immature immune protection. Nevertheless,
most cases of HPV infection are usually temporary, so
in 70 % and 91 % of women infected with HPV, the
virus could be cleared within one or two years, respectively
[33]. The slight increase in the HPV infection rate in older
females might reflect the viral persistence or reactivation of
latent HPV, likely because of the physiological and im-
munological disorders that can result from hormone fluctu-
ations during the menopausal transition [34]. In this study,
the general age distribution showed a first peak of hrHPV
in the age group of 15-year-old patients (30.55 %), then
Table 2 The prevalence of each HPV genotype by the











HPV16 465 4.82 18.02
HPV52 436 4.52 16.90
HPV58 264 2.74 10.23
HPV59 158 1.64 6.12
HPV56 157 1.63 6.09
HPV39 154 1.60 5.97
HPV18 143 1.48 5.54
HPV68 135 1.40 5.23
HPV51 111 1.15 4.30
HPV33 105 1.09 4.07
HPV31 81 0.84 3.14
HPV66 74 0.77 2.87
HPV82 69 0.72 2.67
HPV55 60 0.62 2.33
HPV53 59 0.61 2.29
HPV45 44 0.46 1.71
HPV35 38 0.39 1.47
HPV83 19 0.20 0.74











HPV6 387 4.01 45.80
HPV11 221 2.29 26.15
HPV61 120 1.24 14.20
HPV40 46 0.48 5.56
HPV44 46 0.48 5.44
HPV42 24 0.25 2.84
Significant differences among the proportion of all genotypes using the
chi-squared (χ2) test (P < 0.0001). Multiple comparisons were further performed
using the Bonferoni step-down procedure, and the proportion of the most common
genotypes HPV16 and HPV52 (P= 0.288), as well as the proportion of HPV59,
HPV56, HPV39, HPV18, and HPV68 (P= 0.583) were not significantly different
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gradually decreasing in middle age, which is consistent with
data from Bruni et al. [25]. However, the hrHPV infection
rate was significantly increased in 50–60-year-old individ-
uals compared with women in their 40s, which is a similar
trend that has been observed in most developed countries.
The prosperous economy in most major cities could influ-
ence the culture and sexual behavior of Chinese individuals
[15]. Nonetheless, the exact mechanisms for the increase in
HPV prevalence still remain unclear.
Data concerning the distribution of HPV genotypes is
important for both vaccine development and HPV-based
screening design, particularly for selecting the testing
spectrum of HPV genotypes [35] and detecting multiple
HPV infections. It is a prerequisite for the genotyping
assays in cervical cancer screening programs. However,
few HPV devices have been cleared by the FDA, includ-
ing the Roche Cobas 4800, which also provides limited
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Fig. 4 Region-specific multiple infections of hrHPV by Tellgenplex™ HPV DNA Test
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DNA Test, an established genotyping method [23], was
performed in this survey. By following CAP (College of
American Pathologists) principles, the validation of Tell-
genplex™ HPV DNA Test were conducted compare to
HCII in the molecular biology lab of KingMed, and the
correlations that we detected were found to be (coinci-
dent rate = 90.5 %, Kappa = 0.88).
Consistent with the data generated by some Chinese
population-specific investigations, HPV16, HPV52, and
HPV58 were found to be the dominant hrHPV types
[37, 38]. Compared with the data of Wu et al. [28], a
population-based investigation from five regions (Beijing,
Shanghai, Xinjiang, Henan, and Shangxi) in China, the in-
fection rates of HPV16 (4.82 %), HPV52 (4.52 %), and
HPV58 (2.74 %) were all higher than in the HPV16 (2.9 %),
HPV52 (1.7 %), and HPV58 (1.5 %) strains obtained in this
present study. Regarding the proportion of these three ge-
notypes, except for HPV52 (16.9 % and 11.9 %, P = 0.006),
which is higher than that reported in the present study,
there were no significant differences detected in the propor-
tion of HPV16 (20.2 % and 18.02 %, P = 0.245) or HPV58
(10.8 % and 10.23 %, P = 0.686). The proportion of HPV16
in this survey was even lower than that among the normal
cytology samples reported by Guan et al. and Bruni et al.
(20.4 % and 22.5 %, respectively) [25, 39]. Notably, HPV52
and HPV58 accounted for 27.13 % of infections, which is
markedly higher than the global rate of 14.37 % [39].
Although both HPV52 and HPV58 were all common
among Asian populations, the significance of the two
genotypes remains unknown. Zhao et al. [40] reported
that HPV52 infections are more common among healthy
individuals, whereas HPV58 has been linked to cervical
cancer. Some studies conducted in the South and West
regions of China, which only included CIN or cancer
samples, indicated that HPV58 is more prevalent than
HPV52 [18, 30, 41, 42]. HPV18, apart from HPV16, is
also important for cervical carcinogenesis [43]. However,
in our present study, it was the seventh most common
infection, and the infection rate (1.48 %) was in line
with the study of Wu et al. (P = 0.871) [28]. These find-
ings indicated that in addition to HPV16 and HPV18,
the HPV vaccine in China should also include the
HPV52 and HPV58 genotypes.
In addition to carcinogenesis, many benign cutaneous
warts, mucosal lesions, and low-grade cervical intraepithe-
lial lesions generate a considerable health burden that is
associated with lrHPV infection [44]. Specifically, HPV6
and HPV11 cause 90 % of genital warts, over 95 % of
recurrent respiratory papillomatosis cases, and ~10 %
of early cervical lesions [45]. The infection can become
more serious in immune-compromised individuals [44].
In our present survey, the incidence of HPV6 (4.01 %)
infection was inconsistent with the results of Bruni
et al. [25], who showed that HPV6 was most frequent
among Americans (2.9 %) and was less frequent in Asian
individuals (0.2 %), followed by HPV11 and HPV61.
Characterization of the prevalence of multiple HPV in-
fections might be important for understanding its effects
on cervical carcinogenesis. Herrero et al. [10] reported
that women infected with HPV16 alone were at a similar
or higher risk for cervical cancer than those infected with
both HPV16 and another HPV type. Lee et al. [46] reported
an association between infection with multiple HPV types
and an increased risk of cervical cancer. In a recent study,
Schmitt et al. [47] confirmed that co-infection would in-
crease the duration of infection. Furthermore, patients with
multiple high viral loads showed a 4- to 6-fold increased
risk of cervical precancerous cytological lesions compared
with patients with single high viral loads. In this present
study, 434 hrHPV-positive samples (4.5 %) were multiple-
infections. The incidence was in the same range (3.5–5.3 %)
as was previously reported in China [37], but was higher
than the global average (3.2 %) [25]. Furthermore, the rate
of infection (14.19 %) was lower than reported for both
domestic (25.8 %) [28] and international (20 %) [25]
populations. The most common combinations of two
types were HPV16 +HPV52 (26 cases) and HPV52 +
HPV58 (14 cases), and the genotypes HPV52 and HPV58
were more likely to be involved in co-infections. Regarding
region-specific surveillance, some geographical features
were observed. For example, in Shanghai, a city with a
large internal population, the situation was close to the
world average regarding HPV prevalence, genotypic
distribution, and multiple infections.
This present study confirmed the high overall incidence
of HPV in China and strongly argues for the necessity of
developing national population-based screening programs.
However, the appropriate management of this HPV
screening program for a large number of women with
HPV-positive specimens and the absence of cytological
evidence of cervical pre-cancer or cancer remains a major
concern [48]. HPV genotyping could be an option to stratify
the HPV-positive women. Furthermore, a stainable HPV
detection and close follow-up program for hrHPV carrier
women should be implemented. Thus, more cost-effective
techniques, such as the Cervista™ HR HPV test, COBAS
HPV test, and some other genotyping platforms, might be
good alternatives for molecular detection of HPV [49].
Conclusions
In conclusion, China has large population and a variety
of territories; meanwhile, economic conditions, cultural
habits, and population migrations have dramatically af-
fected Chinese lifestyle and health, for instance, cancers
related to sexual transmitted diseases. Therefore, atten-
tion should be paid to the prevalence of HPV infection
in a timely and regional basis because it has been com-
monly recognized that HPV infection plays a critical role
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in the occurrence of cervical cancer and its increase in-
cidence. These surveillance findings indicated that a na-
tional plan for a cervical screening program is urgently
needed, not only because of the increase in hrHPV in-
fection rate in some previously reported regions, but also
because of the high infection rate in most newly investi-
gated regions. In brief, the most significant findings of
this study are as follows: (1) the prevalence of hrHPV in-
fection has reached a level that cannot be ignored, and
the rate of increase is growing with time; (2) the preva-
lence of hrHPV infection showed population variations in
age and region, and also reflected economic, cultural, and
lifestyle relevance; (3) the HPV16, HPV52, and HPV58
strains consistently constituted the three dominant geno-
types in different Chinese populations, a characteristic
pattern that was significantly different from the epidemio-
logical features in most of industrial countries. These find-
ings defined principles for future proposals for cervical
screening and vaccination in China.
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